York, U.K. 5 July 2021: Abingdon Health plc (AIM: ABDX) (“Abingdon” or “the Company”), a leading international developer and manufacturer of high quality and effective rapid tests, today announces that it has signed a manufacturing and supply agreement with Bioporto A/S (CPH: BIOPOR), an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world.
Under the terms of the 10-year agreement, Abingdon will manufacture the lateral flow strips for Bioporto’s Generic Rapid Assay Device (gRAD) platform, the company’s proprietary patented technology for rapid lateral flow test development. The test which has completed technical transfer will be manufactured by Abingdon Health at its Doncaster facility, following the Company’s expansion of its manufacturing capacity. This will provide Bioporto A/S with immediate access to high volume manufacturing to meet their anticipated global demand for its product.
Chris Yates, CEO of Abingdon Health, commented: “We are delighted to be supporting Bioporto with access to Abingdon’s high volume manufacturing capability. We have built a strong relationship with the team during the transfer of their exceptional lateral flow products into Abingdon Health and are pleased to have secured this long-term manufacturing arrangement. We are pleased to be able to provide our manufacturing expertise and growing capacity to help the deployment of high quality rapid lateral flow tests to the international markets.”
Enquiries:
| Abingdon Health plc | ||
| Chris Yates | Chief Executive Officer | Via Walbrook PR |
| Dr Chris Hand | Non-Executive Chairman | |
| Melanie Ross | Chief Financial Officer | |
| Walbrook PR Ltd | Financial PR | Tel: +44 (0) 20 7933 8787 |
| Paul McManus | [email protected] |
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
https://www.abingdonhealth.com/
